Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact

News

May 5, 2023Blog | Member News, Healthcare, Technology & Innovation

Biogen’s ASL Drug approved by FDA

New England Council member, Biogen, announced that the FDA has approved its drug for amyotrophic lateral sclerosis, or ALS. 

A few months ago, Biogen submitted its new ASL drug, Tofersen, for consideration under the FDA’s accelerated approval pathway. This pathway allows the use of a surrogate endpoint that experts believe is reasonably likely to predict a clinical benefit, even if the benefit has yet to be proven in studies. With this, an advisory committee of experts voted unanimously in favor of accelerated approval for Tofersen and, on Tuesday, Biogen said the FDA had approved the drug. This new drug will be marketed under the name Qalsody and used to treat ALS patients with a mutation in the SOD1 gene. 

“For more than a decade, Biogen has been steadfast in our commitment to pursuing treatments for ALS, and I want to thank the scientists as well as the entire ALS community who have all worked tirelessly to bring this first-of-its-kind treatment to people with SOD1-ALS,” said Chris Viehbacher, president and CEO of Biogen. “Today also marks a pivotal moment in ALS research as we gained, for the first time, consensus that neurofilament can be used as a surrogate marker reasonably likely to predict clinical benefit in SOD1-ALS. We believe this important scientific advancement will further accelerate innovative drug development for ALS.” 

The New England Council commends Biogen for its commitment to the fight against ASL.

Read more from the Boston Business Journal.

Council Related News
Read Article Blog | Member News, Energy & Environment

Dominion Energy Charitable Foundation awards grants to 352 Nonprofits

Read Article Blog | Member News, Higher Education

University of New England announces partnership with Atlantic Hospitality to advance student careers

Read Article Blog | Member News, Higher Education

A study released by the CCIC reveals independent colleges are vital to the state’s economy

Read Article Blog | Member News, Energy & Environment

Unitil and Eversource Announce Water Utility Deals

Read Article Blog | Member News, Technology & Innovation

General Dynamics Electric Boat awarded $12.2 billion contract to boost shipbuilder pay and build two new submarines

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit